Thursday, November 22, 2018

Latest news on Nanotechnology

|Latest News On Nanotechnology|

|Indiana University researchers have discovered that drug-delivering nanoparticles attach to their targets differently based upon their position when they meet |


Indiana University researchers 'camouflaged' a particle nanoprobe as a healthy human t-cell in order to trace the complex molecular 'dance' these particles undergo during cellular binding

The study, printed November. thirteen within the journal ACS Nano, is important since the "movement" of therapeutic particles after they bind to receptor sites on human cells might indicate the effectiveness of drug treatments. The effectiveness of therapy, that uses the body's own system to fight diseases like cancer, depends partly upon the flexibility to "tune" the strength of cellular bonds, for instance.
"In several cases, a drug's effectiveness is not based mostly upon whether or not or not it binds to a targeted receptor on a cell, however powerfully it binds," same Yan Yu, Associate in Nursing prof within the IU town school of Arts and Sciences' Department of Chemistry, WHO LED the study. "The higher we are able to observe these processes, the higher we are able to screen for the therapeutic effectiveness of a drug."
Until this study, researchers thought particles delayed and have become cornered after they absolute to a receptor on a cell.
"But we tend to additionally saw one thing new," Yu said. "We saw the particles turned otherwise based mostly upon after they became cornered in binding to their receptors."
This has ne'er been seen before as a result of, if molecular motion may be a waltz, then scientists were solely looking at one dancer.
To conduct their study, Yu's team introduced dance partners. These were 2 nanoparticles -- one colored inexperienced, the opposite red -- that paired along to make one imaging marker visible beneath a visible radiation magnifier. This "nanoprobe" was then invisible  with a cytomembrane coating taken from a T cell, a kind of white blood corpuscle that plays a job within the body's system.
The two colours allowed the researchers to at the same time observe the "rotational motion" -- circling in situ -- and "translational motion" -- movement across physical area -- of the particle before attaching to the cell.
"We found that the particles began with random rotation, affected to rocking motion, then a circling motion and at last a confined circling motion," Yu said. "The observation of this wide selection of motion motion -- and also the transition from one kind to following at totally different points in time -- is totally new."

|Sources:Indiana University|

NIAID

|Biomedicine 2019|

|March 29-30 2019|

Contact us on : biomedicine2018@gmail.com

Tuesday, November 20, 2018

#Nanotechnology

|Biomedicine 2019|

|Track- Nanotechnology|

#Biomedicine2019
#Hongkong2019
#Submit abstract to the #track
We cordially invite all the participants who are interested in sharing their knowledge and most recent research in the arena of Biomedicine 2019
#Track: #Nanotechnology
At the level of atomic, molecular and macromolecular the development of engineered devices is known as Nanotechnology. Nanoparticles have potential application in medical field including diagnostics and therapeutics. Nanotechnology devices are being developed for diagnosis of cancer and infectious diseases which can help in early detection of the disease
find the link below 
https://biomedicine.conferenceseries.com/abstract-submission.php


Tuesday, November 6, 2018

Latest Research on Tissue engeneering

|Latest Research on Tissue  Engineering|

|Scientists create tiny, biodegradable scaffold to transplant stem cells and deliver drugs|
Rutgers scientists have created a tiny, biodegradable scaffold to transplant stem cells and deliver drugs, which may help treat Alzheimer's and Parkinson's diseases, aging brain degeneration, spinal cord injuries and traumatic brain injuries.
Stem cell transplantation, which shows promise as a treatment for central nervous system diseases, has been hampered by low cell survival rates, incomplete differentiation of cells and limited growth of neural connections.

It's been a major challenge to develop a reliable therapeutic method for treating central nervous system diseases and injuries," said study senior author KiBum Lee, a professor in the Department of Chemistry and Chemical Biology at Rutgers University-New Brunswick. "Our enhanced stem cell transplantation approach is an innovative potential solution."
The researchers, in cooperation with neuroscientists and clinicians, plan to test the nano-scaffolds in larger animals and eventually move to clinical trials for treating spinal cord injury. The scaffold-based technology also shows promise for regenerative medicine.

|SOURCES:https://www.rutgers.edu/|

|Biomedicine 2019|

|Hongkong 2019 29-30|


Monday, November 5, 2018

#Frontier Biomedicine

|Biomedicine 2019|

|Submit your  abstract to the Track|

|Meet Expert  Unleash your Research|

|#Frontier Biomedicine|

By using the chemical physical and biological methods the organs and the tissue systems can be developed the process is known as tissue systemPathology is both a pure and an applied science and in the NHS setting is responsible for providing diagnostic laboratory tests on tissue, blood and other fluids, and for using laboratory tests to assess patients’ responses to treatment.
  • Pathology
  • Tissue engineering
  • Cell biology
  • Parasitology
  • Virology
  • Systems biomedicine

Choose track #pharmacognosy  #Immunopharmacology

#Industrialpharmacy #Nanotechnology #Molecularbiomedicine

#Pharmaceutical science

https://biomedicine.conferenceseries.com/abstract-submission.php

Hongkong

March2019 29-30


Friday, November 2, 2018

#Call for oral presentation #video presentation #posterpresentation

|Biomedicine 2019|

|Be A Part of Biomedicine Family|

|Unleash Your Research


#Biomedicine is back with many #amazing #personalities presenting their talk on some #Excitement # and #Oral presentation  #videopresentation  #posterpresentation #biomedicine2019 #sessions
To know more about our #confirmed #speakers
PS: https://biomedicine.conferenceseries.com/abstract-submission.php
#Speaker
 #opportunities are still available.

#Submit your #abstract ,#Register and be a part of #Biomedicine family


 |March 2019 29-30|

|Hong kong|

Tuesday, October 30, 2018

#Personalised Medicine

|Track:9- Personalised Medicine|

|Opportunities to learn new things and gain a profound |

|calling all the Pharmaceutical researchers#scholars#young researchers#Business delegates to unleash your newest research and interact with the world class mentors and peers|

The patients are separated into different groups according to their medical decision, practices, intervention or their risk of disease, the term is used known as personalized medicine. It is also called precision medicine, stratified medicine and p4 medicine. In personalised medicine, based on the context of a patient’s genetic content or other molecular or cellular analysis diagnostic testing is often employed for selecting appropriate and optimal therapies
  • Paths of Biomarkers
  • Clinical Case Reports
  • Preventive Medicines
  • Personalized Medicine & its Innovations
  • Personalized Drug Therapy
  • Genomics & Personalized Medicine









Monday, October 29, 2018

#Latest research on Molecular Biomedicine

|Molecular Biomedicine Latest Research

|New AUC published for lumbar puncture and spinal fluid analysis in Alzheimer's diagnosis|

Alzheimer's disease is commonly diagnosed by a thorough examination of physical health, medical history and assessment of memory, thinking and reasoning. Lumbar puncture, while not currently in routine clinical practice in the U.S., is anticipated to be a safe and cost-effective way to retrieve cerebrospinal fluid (CSF) to test for biological markers of Alzheimer's disease, potentially delivering valuable diagnostic information to clinicians and their patients earlier in the course of the disease
Appropriate uses of lumbar puncture:
  • A patient has subjective cognitive decline (SCD) and is considered to be at an increased risk for Alzheimer's disease based on indicators that include a persistent decline in memory, younger onset age (>60), onset in the last 5 years and others. The decision to perform CSF biomarker testing in this case should be individualized and most strongly supported when the individual, family and clinician all are concerned about the patient's cognitive decline.
  • A patient has mild cognitive impairment (MCI) that is persistent, progressive and unexplained. MCI includes mild deficits on cognitive testing but no change in functional abilities.
  • A patient has symptoms that suggest possible Alzheimer's disease, meaning the dementia could be due to another cause.
  • A patient has MCI or dementia with onset at an early age (<65).
  • A patient meets core clinical criteria for probable Alzheimer's disease with typical age of onset.
  • A patient's dominant symptom is an unexplained change in behavior, such as delusions and delirium, and an Alzheimer's disease diagnosis is being considered.
The AUC includes suggestions from the workgroup on implementing the criteria in clinical practice. They recommend that CSF biomarker testing be done by dementia experts who can determine the appropriateness of the test, educate the patient and family about the benefits and risks, ensure the procedure follows established guidelines, and integrate the results into the patient's treatment plan